Products
Online Inquiry
Tivozanib
Cat. No.:
0225LY-0539
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Tivozanib is an orally bioavailable VEGFR 1, 2, and 3 inhibitor investigated for its potential to hinder angiogenesis and tumor growth.
Synonym:
AV-951; KRN951; 475108-18-0; 1-(2-Chloro-4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-3-(5-methylisoxazol-3-yl)urea; Urea, N-(2-chloro-4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)-N'-(5-methyl-3-isoxazolyl)-
CAS No.:
475108-18-0
Compound CID:
9911830
Formula:
C22H19ClN4O5
Formula Weight:
454.86
Specification
Targets&IC50:
PDGFRα: 40 nM; EphB2: 24 nM; VEGFR1: 30 nM; VEGFR2: 6.5 nM; VEGFR3: 15 nM
Relative Density:
1.421 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Tivozanib can be used in renal cell carcinoma research to evaluate its high potency and selectivity against VEGF receptors.
Library Information
Target:
VEGFR; PDGFR; Ephrin receptor
Receptor:
EphB2; PDGFRα; VEGFR1; VEGFR2; VEGFR3
Pathways:
Angiogenesis; Tyrosine kinase/adaptors
Plate Number:
AOCL-8
Plate Location:
a3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
38.33 mg/mL; 84.27 mM
Ethanol Max Solubility:
<1 mg/mL
ALogP:
4.039
HBA_Count:
7
HBD_Count:
2
Rotatable Bond:
6
